Background
Rituximab, high‐dose methotrexate (HD‐MTX), procarbazine and vincristine (R‐MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R‐MPV have not yet been investigated. Herein, we investigated the correlation of
MYD88
L265P and
CD79B
Y196 mutations, which are the most frequently found molecular alterations in PCNSL, with prognosis of patients with PCNSL treated with R‐MPV.
Methods
We investigated the long‐term clinical course and status of
MYD88
and
CD79B
genes in 85 patients with PCNSL treated with R‐MPV or HD‐MTX treatment, and the correlation of these genetic mutations with prognosis.
Results
R‐MPV achieved an excellent tumor control rate (61.6% and 69.9% of 5‐year progression‐free and overall survival rates, respectively). While
MYD88
L265P mutation had no significant effect on survival, patients with
CD79B
Y196 mutations exhibited prolonged survival (
p
< 0.05). However, the association of
CD79B
Y196 mutation with a better prognosis was not observed in the HD‐MTX cohort, which indicated that
CD79B
Y196 mutation was a predictive marker for a favorable response to R‐MPV. Furthermore, we established an all‐in‐one rapid genotyping system for these genetic mutations.
Conclusions
In conclusion,
CD79B
Y196 mutation is a potent predictive marker for favorable response to R‐MPV in PCNSL. The rapid identification of
MYD88
L265P and
CD79B
Y196 mutations can be helpful not only for the accurate molecular diagnosis of PCNSL but also for the prediction of response to R‐MPV.